专家论坛

银屑病关节炎的诊治现状与挑战

展开
  • 上海交通大学附属第六人民医院风湿免疫科,上海 200233

收稿日期: 2021-11-08

  网络出版日期: 2022-08-09

本文引用格式

戴生明 . 银屑病关节炎的诊治现状与挑战[J]. 内科理论与实践, 2022 , 17(03) : 186 -189 . DOI: 10.16138/j.1673-6087.2022.03.002

参考文献

[1] FitzGerald O, Ogdie A, Chandran V, et al. Psoriatic arthritis[J]. Nat Rev Dis Primers, 2021, 7(1): 59.
[2] Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome[J]. Ann Rheum Dis, 2005, 64 Suppl 2:ii14-ii17.
[3] van der Heijde D, Gladman DD, Kavanaugh A, et al. Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research[J]. Arthritis Res Ther, 2020, 22(1): 18.
[4] McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study[J]. Rheumatology (Oxford), 2003, 42(6): 778-783.
[5] Charlton R, Green A, Shaddick G, et al. Risk of type 2 diabetes and cardiovascular disease in an incident cohort of people with psoriatic arthritis: a population-based cohort study[J]. Rheumatology(Oxford), 2019, 58(1): 144-148.
[6] Favarato MH, Mease P, Gonçalves CR, et al. Hypertension and diabetes significantly enhance the risk of cardiovascular disease in patients with psoriatic arthritis[J]. Clin Exp Rheumatol, 2014, 32(2): 182-187.
[7] Szentpetery A, Healy GM, Brady D, et al. Higher coronary plaque burden in psoriatic arthritis is independent of metabolic syndrome and associated with underlying disease severity[J]. Arthritis Rheumatol, 70(3): 396-407.
[8] Rosen CF, Mussani F, Chandran V, et al. Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone[J]. Rheumatology, 2012, 51(3):571-576.
[9] Chen Z, Xu Y, Chen M, et al. Gout augments the risk of cardiovascular disease in patients with psoriasis[J]. Front Immunol, 2021, 12: 703119.
[10] 丁晓岚, 王婷琳, 沈佚葳, 等. 中国六省市银屑病流行病学调查[J]. 中国皮肤性病学杂志, 2010, 24(7): 598-601.
[11] Reich K, Krüger K, Mössner R, et al. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis[J]. Br J Dermatol, 2009, 160(5): 1040-1047.
[12] Guillen Astete CA, Gaite Gonzalez I, Zurita Prada PA, et al. Delay and diagnostic pathway of patients with psoriatic arthritis in Spain[J]. Reumatol Clin (Engl Ed), 2020, 17(9): 525-529.
[13] Karmacharya P, Wright K, Achenbach SJ, et al. Diagnostic delay in psoriatic arthritis[J]. J Rheumatol, 2021, 48(9): 1410-1416.
[14] Cui R, Chen M, Li X, et al. Assessment of four screening tools and retrieval of key questions to detect undiagnosed psoriatic arthritis in Chinese patients with psoriasis[J]. J Dermatol, 2022, 49(6): 615-623.
[15] Tinazzi I, Adami S, Zanolin EM, et al. The early psoriatic arthritis screening questionnaire: a simple and fast method for the identification of arthritis in patients with psoriasis[J]. Rheumatology, 2012, 51(11): 2058-2063.
[16] Ibrahim GH, Buch MH, Lawson C, et al. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire[J]. Clin Exp Rheumatol, 2009, 27(3): 469-474.
[17] Lindqvist UR, Alenius GM, Husmark T, et al. The Swedish early psoriatic arthritis register- 2-year followup[J]. J Rheumatol, 2008, 35(4): 668-673.
[18] Kane D, Stafford L, Bresnihan B, et al. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience[J]. Rheumatology, 2003, 42(12): 1460-1468.
[19] Kane D, Pathare S. Early psoriatic arthritis[J]. Rheum Dis Clin North Am, 2005, 31(4): 641-657.
[20] Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis[J]. Ann Rheum Dis, 2015, 74(6): 1045-1050.
[21] Weisman MH, Witter JP, Reveille JD. The prevalence of inflammatory back pain: population-based estimates from the US National Health and Nutrition Examination Survey, 2009-10[J]. Ann Rheum Di, 2013, 72(3): 369-373.
[22] Dai SM, Han XH, Zhao DB, et al. Prevalence of rheumatic symptoms, rheumatoid arthritis, ankylosing spondylitis, and gout in Shanghai, China[J]. J Rheumatol, 2003, 30(10): 2245-2251.
[23] Xiang YJ, Dai SM. Prevalence of rheumatic diseases and disability in China[J]. Rheumatol Int, 2009, 29(5): 481-490.
[24] Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis[J]. Rheumatology (Oxford), 2012, 51(8):1368-1377.
[25] Ramiro S, Smolen JS, Landewé R, et al. Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis[J]. Ann Rheum Dis, 2016, 75(3): 490-498.
[26] Acosta Felquer ML, Coates LC, Soriano ER, et al. Drug therapies for peripheral joint disease in psoriatic arthritis: a systematic review[J]. J Rheumatol, 2014, 41(11): 2277-2285.
[27] Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial[J]. Arthritis Rheum, 2004, 50(6): 1939-1950.
[28] Zardin-Moraes M, da Silva ALFA, Saldanha C, et al. Prevalence of psoriatic arthritis patients achieving minimal disease activity in real-world studies and randomized clinical trials[J]. J Rheumatol, 2020, 47(6): 839-846.
[29] Chen M, Zhang H, Chen Z, et al. Perceptions of rheumatologists on diagnosis of psoriatic arthritis in China[J]. Front Immunol, 2021, 12:733708.
文章导航

/